Article Versions Notes

Rostama B, Beauchemin M, Bouchard C, Bernier E, Vary CPH, May M, Houseknecht KL. Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice. International Journal of Molecular Sciences. 2020; 21(24):9362. https://doi.org/10.3390/ijms21249362

Rostama, Bahman, Megan Beauchemin, Celeste Bouchard, Elizabeth Bernier, Calvin P. H. Vary, Meghan May, and Karen L. Houseknecht. 2020. "Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice" International Journal of Molecular Sciences 21, no. 24: 9362. https://doi.org/10.3390/ijms21249362

Rostama, B., Beauchemin, M., Bouchard, C., Bernier, E., Vary, C. P. H., May, M., & Houseknecht, K. L. (2020). Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice. International Journal of Molecular Sciences, 21(24), 9362. https://doi.org/10.3390/ijms21249362